Table 10.

IOP-lowering effects of G2 and marketed formulation after treatment.

Time (hr)	IOP (mmHg) lowering effects of G2 and marketed formulation
	Group II (G2)		Group III (marketed Pilopine HS gel)
	R	L	R	L
0	40.47 ± 0.42	40.47 ± 0.04	40.07 ± 0.19	40.07 ± 0.02
2	40.47 ± 0.42	35.12 ± 0.17	40.07 ± 0.19	30.95 ± 1.68
4	40.47 ± 0.42	27.89 ± 0.28	40.07 ± 0.19	27.37 ± 2.32
6	40.47 ± 0.42	23.85 ± 0.31	40.07 ± 0.19	21.69 ± 0.45
7	40.47 ± 0.42	21.20 ± 0.53	40.07 ± 0.19	17.42 ± 1.12
8	40.47 ± 0.42	19.28 ± 0.06	40.07 ± 0.19	20.95 ± 3.21
9	40.47 ± 0.42	17.98 ± 1.35	40.07 ± 0.19	21.69 ± 0.57
10	40.47 ± 0.42	19.54 ± 2.31	40.07 ± 0.19	24.23 ± 1.12
11	40.47 ± 0.42	20.94 ± 0.96	40.07 ± 0.19	28.96 ± 4.96
24	40.47 ± 0.42	21.93 ± 1.24	40.07 ± 0.19	40.01 ± 0.43